A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

BackgroundTreatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adu...

Full description

Bibliographic Details
Main Authors: Johannes T. Reckweg, Cees J. van Leeuwen, Cécile Henquet, Therese van Amelsvoort, Eef L. Theunissen, Natasha L. Mason, Riccardo Paci, Theis H. Terwey, Johannes G. Ramaekers
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Psychiatry
Subjects:
psychedelics
5-MeO-DMT
treatment-resistant depression
individualized dosing
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1133414/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1133414/full

Similar Items